Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening

BACKGROUND: Higher infliximab trough levels (TLs) correlate with better clinical, inflammatory, and endoscopic outcomes among inflammatory bowel disease (IBD) patients. Although standard scheduled infliximab therapy regimen consists of infusions at pre-defined time-points (weeks 0, 2, 6, and every 8...

Descripción completa

Detalles Bibliográficos
Autores principales: Ben-Shatach, Zohar, Ziv-Baran, Tomer, Fudim, Ella, Yavzori, Miri, Picard, Orit, Levartovsky, Asaf, Selinger, Limor, Weiss, Batia, Kopylov, Uri, Eliakim, Rami, Ungar, Bella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133860/
https://www.ncbi.nlm.nih.gov/pubmed/35646158
http://dx.doi.org/10.1177/17562848221083395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133860/
https://www.ncbi.nlm.nih.gov/pubmed/35646158
http://dx.doi.org/10.1177/17562848221083395

Ejemplares similares